On this page
Hydrocortisone Acetate Cream
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Hydrocortisone Acetate | 20 mg/g | 1291082 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 040396-001 | MICORT-HC | CREAM | HYDROCORTISONE ACETATE | Prescription | — |
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 2 | Manufacturing (CMC) | Approved | June 28, 2012 | — |
| Original application | 1 | Approved | February 27, 2001 | — |
Review documents
- 0 · Original application · February 27, 2001
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260729). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Topical corticosteroids are generally applied to the affected areas as a thin film two to four times daily depending on the severity of the condition. Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the used of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressing. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions hypopigmentation, period dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Description
openFDA Drug LabelingDESCRIPTION Hydrocortisone Acetate Cream USP is a topical preparation containing hydrocortisone acetate 2.5% w/w in a water washable cream base containing cetostearyl alcohol, ceteth 20, light mineral oil, petrolatum, propylparaben, butylparaben, citric acid, sodium citrate, and purified water. Topical corticosteroids are anti-inflammatory and anti-pruritic agents. The structural formula, the chemical name, molecular formula and molecular weight for the active ingredient is presented below: Structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. ( See PRECAUTIONS )
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Hydrocortisone Acetate Cream 2.5% 1 oz (28.4 g) tube NDC 71297-241-01 Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Protect from freezing. Keep out of reach of children. Keep tube closed when not in use. Rev 2/2025 Manufactured for: Allegis Holdings LLC Canton, MS 39046 Protected under U.S. Patent No. 5,635,497.
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: HYDROCORTISONE ACETATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 71297-241-01 | 71297-241 | Allegis Holdings LLC | 28.4 g in 1 CARTON (71297-241-01) | July 28, 2025 |
| 28595-050-01 | 28595-050 | Allegis Pharmaceuticals, Inc. | 28.4 g in 1 CARTON (28595-050-01) | July 29, 2026 |
| 71297-241 | 71297-241 | Allegis Holdings LLC | — | July 28, 2025 |
| 28595-050 | 28595-050 | Allegis Pharmaceuticals, Inc. | — | July 29, 2026 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 10 sections on this page.